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Abstract
Congenital amegakaryocytic thrombocytopenia (CAMT) is an inher-
ited disorder characterized at birth by thrombocytopenia with
reduced megakaryocytes, which evolves into generalized bone
marrow aplasia during childhood. Although CAMT is genetically
heterogeneous, mutations of MPL, the gene encoding for the
receptor of thrombopoietin (THPO), are the only known disease-
causing alterations. We identified a family with three children
affected with CAMT caused by a homozygous mutation (p.R119C)
of the THPO gene. Functional studies showed that p.R119C affects
not only ability of the cytokine to stimulate MPL but also its
release, which is consistent with the relatively low serum THPO
levels measured in patients. In all the three affected children,
treatment with the THPO-mimetic romiplostim induced trilineage
hematological responses, remission of bleeding and infections, and
transfusion independence, which were maintained after up to
6.5 years of observation. Recognizing patients with THPO muta-
tions among those with juvenile bone marrow failure is essential
to provide them with appropriate substitutive therapy and prevent
the use of invasive and unnecessary treatments, such as
hematopoietic stem cell transplantation or immunosuppression.
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Introduction
Congenital amegakaryocytic thrombocytopenia (CAMT, MIM
604498) is an inherited disorder characterized at birth by severe
thrombocytopenia with reduced/absent bone marrow megakary-
ocytes, and subsequently evolution, usually within the first decade
of life, into pancytopenia due to trilineage bone marrow aplasia
(Ballmaier et al, 2003; Ballmaier & Germeshausen, 2011). CAMT is
fatal unless children are treated with allogeneic hematopoietic stem
cell transplantation (HSCT).
The majority of CAMT cases are caused by biallelic mutations in
the gene (MPL) encoding for the myeloproliferative leukemia virus
oncogene (MPL) receptor, which abolish or severely impair the
interaction of the receptor with its ligand thrombopoietin (THPO)
(Ihara et al, 1999; Ballmaier et al, 2001; Savoia et al, 2007;
Ballmaier & Germeshausen, 2009). The clinical course of CAMT
reflects the non-redundant role of the THPO/MPL pathway in
megakaryocyte and platelet production since birth and in mainte-
nance of the multipotent stem cell compartment in the post-natal
hematopoiesis (Ballmaier & Germeshausen, 2011; Hirata et al, 2013).
Of note, a proportion of patients with the clinical picture of CAMT
does not carry mutations in MPL, suggesting that the disease is genet-
ically heterogeneous. It has been hypothesized that the patients with
normal MPL have alterations in genes playing a role upstream or
downstream of the receptor (Ballmaier & Germeshausen, 2011;
Geddis, 2011). Considering that mice lacking Thpo have a similar
phenotype as those lacking Mpl (Carver-Moore et al, 1996), THPO is
a strong candidate.
A homozygous missense mutation in THPO (p.R38C) was previ-
ously reported in a family with a recessive form of aplastic anemia
(Dasouki et al, 2013). Very recently, two other homozygous THPO
mutations (p.R99W and p.R157*) have been associated with
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inherited bone marrow failure syndrome in three unrelated pedi-
grees. Two affected individuals from these families were success-
fully treated by administration of the MPL agonist romiplostim (Seo
et al, 2017).
Here, we report a family where the clinical picture of CAMT
is caused by a novel homozygous mutation in THPO. We show
that the mutation significantly impairs secretion of the cytokine.
Moreover, activity of the mutant THPO was reduced by about
50%, consistent with defective stimulation of the signaling path-
ways downstream of the MPL receptor. The three affected chil-
dren were all treated with romiplostim, resulting in sustained
trilineage response, which was maintained after an up to 6.5-year
follow-up.
Results
Clinical features of the family and response to romiplostim of
the affected children
The propositus is a male born to first cousin parents of Egyptian
origin who presented in July 2009, at the age of 3.5 years, with
ecchymotic patches. His physical examination showed pre-auricular
skin tags and left eye divergent squint. No other physical abnormali-
ties were found. Blood cell count revealed very severe thrombocy-
topenia, hyporegenerative anemia (reticulocyte count 22.8 × 109/l),
and severe neutropenia (Table 1). Microscopy evaluation of periph-
eral blood films did not identify any cytomorphological abnormali-
ties, and platelet size was normal (Noris et al, 2014). Bone marrow
examination showed hypocellularity with very rare immature
megakaryocytes, and conventional marrow cytogenetics showed
normal karyotype. After exclusion of Fanconi anemia (no sponta-
neous and diepoxybutane-induced chromosome breakage) and
paroxysmal nocturnal hemoglobinuria (normal CD55/CD59 expres-
sion in granulocytes and erythrocytes), a diagnosis of idiopathic
aplastic anemia was made.
Shortly after, the propositus started to suffer from recurrent
major hemorrhages (epistaxis, gum, and rectal bleeding) and recur-
rent severe infectious episodes (febrile neutropenia or otitis media
occurring every 1–2 months), which required frequent hospital
admissions and multiple platelet and red blood cell transfusions.
Due to the severity of the clinical picture, HSCT was considered and
proband’s relatives were investigated. Blood cell counts were
normal in the parents, while severe isolated thrombocytopenia was
found in the 7-month-old brother (Table 1). In this subject, periph-
eral blood cell morphology was normal and bone marrow examina-
tion showed a remarkably decreased number of megakaryocytes
without other significant abnormalities.
Given the lack of a family donor for HSCT, the propositus was
treated with cyclosporine A for 4 months, without any response,
and then with oxymetholone, again without any improvement. Due
to the severe bleeding symptoms and the need for very frequent
platelet transfusions, as well as to the lack of other available thera-
peutic options, in June 2010, at the age of 4.4 years, the propositus
was started on empirical treatment with romiplostim. Romiplostim
was given at the dose of 1 lg/kg/week for 3 months with clear and
rapid trilineage improvement of pancytopenia. Afterward, because
of difficulties in accessing to healthcare facilities, the patient
received the dose of 4 lg/kg once a month. Figure 1 shows hemo-
globin concentration, leukocyte count, and platelet count before and
during romiplostim administration. After starting romiplostim, all of
these parameters were stably above the values observed before
treatment. The differential count was performed only on some
visits: The mean neutrophil count was 0.7 × 109/l (range 0.3–1.1)
in the 12 measurements before romiplostim and 1.7 × 109/l (range
1.1–2.9) in the eight available measurements during treatment
(P < 0.005). Most importantly, no further spontaneous bleeding
events and infectious episodes were recorded and no further trans-
fusion needed during romiplostim administration. The patient is
currently on treatment, and the hematological and clinical response
is maintained after a follow-up of 6.5 years.
At the age of 1.6 years, the proband’s brother started to present
with recurrent spontaneous bleeding requiring platelet transfusions.
In view of the good response obtained in the propositus, in Septem-
ber 2010, he was started on romiplostim (4 lg/kg once a month).
He achieved good platelet response (platelet count between 30 and
100 × 109/l) and remission of bleedings with stable independence
from transfusions that was maintained after a 6.3-year follow-up.
Recently, the proband’s parents gave birth to a third, apparently
normal child. At the age of 2 months, she developed a hematoma at
the site of vaccination. Blood cell counts revealed anemia and
severe thrombocytopenia with normal blood cell morphology. She
Table 1. Clinical features and blood counts of the proband and family members at the first examination.
Father Mother Proband 1st sibling 2nd sibling
Age (months)/Gender 42/M 7/M 2/F
Clinical presentation None None Spontaneous bleeding,
infections
None Bleeding at vaccination
Hemoglobin (g/dl) 13.6 12.3 7.8 12.5 8.2
Red blood cells (×1012/l) 4.27 3.83 2.28 4.27 2.71
Mean corpuscular volume (fl) 91.4 91.6 100 83.4 84.9
White blood cells (×109/l) 5 9.6 5.4 11.7 9.5
Neutrophils (×109/l) 2 6.6 0.3 3.34 2.7
Platelets (×109/l) 197 193 3 26 27
Platelet diameter, mean/2.5th–97.5th (lm)a 3.3/2.3–5.2 2.7/1.6–4.8 3.1/1.8–4.9 2.6/1.6–3.9 2.7/1.9–4.2
aNormal values: 2.6/1.6–3.9 lm (Noris et al, 2014).
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was started on romiplostim in October 2015, with good platelet and
hemoglobin response. She is presently receiving romiplostim 4 lg/
kg monthly with platelet counts ranging between 30 and 60 × 109/l
and hemoglobin concentration between 9.9 and 12.3 g/dl. She has
no spontaneous bleeding.
Due to logistic difficulties, platelet count was not regularly
measured at fixed times during romiplostim treatment. For this
reason, wide variations in platelet counts were observed in all the
treated children during the monthly administration (Fig 1). In
Table 2, we report the changes in blood counts observed 1 week
after the monthly administration of romiplostim (4 lg/kg), showing
that the short-term effect of the treatment was a consistent signifi-
cant increase in platelet counts. No side effects attributable to romi-
plostim were observed in any of the three children.
Identification of the p.R119C THPO in the pedigree
Based on the clinical pictures of the three patients suggesting a
defect of the THPO/MPL pathway, we screened for mutation both
the MPL and THPO genes in the proband. While no variants were
found in MPL, we identified the homozygous c.355C>T variant in
THPO (p.R119C). Consistent with recessive inheritance of the
phenotype, the proband’s siblings were homozygous and the
parents were heterozygous for the variant (Fig EV1). The p.R119C
is not reported in the SNP (ncbi.nlm.nih.gov/SNP), 1000 Genome
(1000genomes.org), and ExAC (exac.broadinstitute.org) databases.
The potential effect of the amino acid substitution on protein function
was evaluated using different pathogenicity prediction programs,
such as CADD (score 32), Mutation Taster (disease-causing muta-
tion), Mutation Assessor (neutral), and SIFT (not tolerated),
suggesting that p.R119C is likely to be pathogenic.
The p.R119C is predicted to affect THPO interaction with MPL
Structural bioinformatic analysis showed that residue R119 (R98 in
the mature protein after removal of the leader peptide) is within the
N-terminal region that is involved in the binding of THPO to its
receptor MPL. In particular, the binding domain of THPO is a 4-
helices ribbon bundle domain and R119 resides in the middle of
helix C (Fig EV2). This residue is highly conserved not only
throughout species but also in the receptor binding domain of the
homologous human erythropoietin (EPO), which shares 23%
sequence homology with THPO (Fig EV2).
We analyzed the structure of the receptor binding domain of
THPO in complex with a neutralizing antibody fragment (PDB
1V7M) (Feese et al, 2004). In this structure, although R119 is not
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Figure 1. Time course of hemoglobin level (Hb), white blood cell count (WBC), and platelet count (Plt) in the propositus before and during romiplostim
administration.
Romiplostim was started at the dosage of 1 lg/kg/week, and this schedule was maintained for 3 months. Then, a dose of 4 lg/kg was given in a monthly administration. The
platelet count had wide oscillations that derived, at least partially, from the variability of the time elapsed between the drug administrations and the measurements of blood
count.
Table 2. Representative changes in blood counts 1 week after monthly administration of romiplostim 4 lg/kg.
Proband 1st sibling 2nd sibling
Before After Before After Before After
Hemoglobin (g/dl) 12.3 13.4 12.6 12.7 8.8 9.7
White blood cells (×109/l) 5.2 6.6 8.4 8.7 11.3 10.5
Neutrophils (×109/l) 1.5 1.6 2.4 2.9 1.7 2.6
Platelets (×109/l) 43 94 28 86 20 65
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involved in intermolecular interactions that could be essential for
the correct folding of the domain, it forms a salt bridge with the
side chain of D31 of the antibody fragment (Fig EV2). A similar
interaction is also observed in the structure of EPO in a complex
with its receptor. In this case, the analogous arginine (R103) is
involved in several polar interactions that make this residue a key
player for binding to its receptor (Fig EV2) (PDB 1EER) (Syed
et al, 1998). Therefore, it is reasonable to hypothesize that the
p.R119C mutation does not affect the folding of THPO but the
interaction with MPL.
The p.R119C affects both secretion of THPO and
THPO/MPL signaling
We investigated the consequences of p.R119C on the THPO function
using the UT7-TPO human megakaryoblastic leukemia cells, an
engineered line stably expressing MPL that completely depends on
THPO for growth and survival (Komatsu et al, 1996; Komatsu,
2004). We first transfected the wild-type or p.R119C THPO in
HEK293T cells to produce THPO-conditioned culture supernatants.
We also tested the p.R38C variant that was previously identified in a
family with recessive aplastic anemia to compare the effects of the
two substitutions (Dasouki et al, 2013). Immunoblotting showed
that the three exogenous THPO forms were efficiently expressed in
HEK293T cells, with the mutant proteins expressed even at slightly
higher levels than the wild type (Fig 2A–D).
We then probed the ability of the different THPO-conditioned
HEK293T culture supernatants in sustaining the growth of the
UT7-TPO cells. After incubation with medium containing equal
amounts (0.5 or 1.0 ll) of wild-type or mutant supernatants, the
UT7-TPO proliferation induced by both mutant supernatants was
strongly reduced compared to that promoted by the wild type
(Fig 3). Therefore, we measured the THPO concentrations in the
HEK293T culture supernatants and found that the THPO concentra-
tion in the conditioned media containing both mutants was much
lower than that in the wild-type sample (about 23-fold lower for
both the p.R119C and the p.R38C) (Table 3). Since the THPO
expression levels in the HEK293T cellular lysates were similar
between wild type and mutants (or even higher for the mutant
forms) (Fig 2A–D), we hypothesized that the two variants interfere
with the secretion of THPO from the intracellular to the extracellu-
lar compartment.
To investigate whether the p.R119C or p.R38C substitutions
could instead affect stability of THPO protein, we studied stability of
wild-type and mutant forms using the cycloheximide chase assay
(Te´treault et al, 2016; Zhang et al, 2016). After blocking de novo
protein synthesis in HEK293T cells by treatment with cyclohex-
imide, the kinetics of degradation of the wild-type and mutant
THPOs were assessed over the subsequent 48 h. The assay showed
that the mutant proteins have similar stability to that of the wild-
type form (Fig 4A and B).
To investigate the ability of the p.R119C mutant in stimulating
MPL, we then performed the proliferation assay by incubating UT7-
TPO cells with the same concentrations of wild-type or mutant
THPO. We found that the p.R119C THPO induced a significantly
lower UT7-TPO proliferation compared to the wild type at each of
the three different THPO concentrations tested (60, 120, or 240 pg/
ml) (Fig 5). The mean activity of the p.R119C was 52%  7
(P < 0.05), 53%  9 (P < 0.05), and 45%  4 (P < 0.005) of the
wild-type THPO, respectively. Similar results were obtained with
the p.R38C mutant (Fig 5).
Finally, to support the results obtained with the proliferation
assay, we stimulated UT7-TPO cells with wild-type or mutant
HEK293T supernatants and investigated the phosphorylation status
of key signaling kinases downstream of the MPL receptor, such as
STAT5, ERK1/2, and AKT (Hitchcock & Kaushansky, 2014). The
analysis confirmed that both p.R119C and p.R38C THPO induce
defective activation of all the investigated intracellular signaling
kinases (Fig 6A and B).
Serum THPO levels are not increased in patients
Thrombopoietin levels measured in the sera of the two older
siblings collected before romiplostim administration were within the
normal range. In particular, THPO concentration was 10.9 pg/ml in
the proband and 14.1 pg/ml in his brother. The serum THPO levels
obtained in 50 consecutive healthy subjects ranged from 6.9 to
54.4 pg/ml (mean: 14.6) (Noris et al, 2011). Since the serum THPO
level is negatively regulated by megakaryocytes/platelet mass, it is
always markedly increased in all forms of bone marrow aplasia-
hypoplasia, including the CAMT form caused by MPL mutations
(Dame, 2001; Ballmaier & Germeshausen, 2009; Olnes et al, 2012),
further supporting the hypothesis that production of THPO is defec-
tive in our patients.
▸Figure 2. Transfection of constructs harboring the wild-type or mutant THPO cDNAs induced efficient expression of THPO proteins in HEK293T cells.A Representative images of immunoblotting of HEK293T cell lysates prepared 24 and 48 h after transfection with wild-type (WT) or mutant (p.R119C and p.R38C)
THPO-expressing or empty vectors and then pooled into a ratio of 1:1 (Dasouki et al, 2013). THPO cDNAs were tagged with the FLAG epitope. b-Actin was used as
loading control.
B Densitometric analysis of the bands obtained by immunoblotting of HEK293T cell lysates prepared 24 and 48 h after transfection and then pooled into a ratio of 1:1.
Immunoblotting was performed on cells collected after n = 3 independent transfection experiments. THPO levels are expressed as FLAG/b-actin ratio and THPO/
b-actin ratio.
C Representative images of immunoblotting of HEK293T cell lysates prepared 24 and 48 h after transfection with wild-type or mutant THPO-expressing or empty
vectors and then analyzed separately (24 and 48 h).
D Densitometric analysis of the bands obtained by immunoblotting of HEK293T cell lysates prepared 24 and 48 h after transfection and then analyzed separately.
Immunoblotting was performed on cells collected after n = 3 independent transfection experiments. Samples derive from the same experiment, and blots were
processed in parallel.
Data information: In (B, D), data are presented as means  SD. The asterisk (*) indicates a P-value < 0.05 with respect to WT (two-tailed Student’s t-test). The exact
P-values are reported in Appendix Table S1.
Source data are available online for this figure.
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Discussion
In humans, the THPO/MPL pathway is essential not only for platelet
production since birth but also for preservation of the integrity of
the multipotent stem cell compartment in the post-natal hemopoi-
esis (Ballmaier & Germeshausen, 2011; Hirata et al, 2013; Hitchcock
& Kaushansky, 2014). The phenotype of CAMT is the most convinc-
ing proof of these non-redundant and non-synchronous roles of this
pathway. In fact, patients with CAMT not only have congenital
hypo-megakaryocytic thrombocytopenia but also develop during
childhood further cytopenias until progression to generalized bone
marrow aplasia. At present, loss-of-function mutations in MPL are
the only known cause of CAMT, although some observations
indicate that the disorder is genetically heterogeneous (Ballmaier &
Germeshausen, 2011; Geddis, 2011).
In the Egyptian pedigree reported in this paper, we show that a
homozygous loss-of-function variant in THPO (p.R119C) induces a
phenotype similar to that caused by MPL mutations. Indeed, the
oldest of the three affected siblings presented with trilineage bone
marrow hypoplasia, while the younger ones had isolated thrombo-
cytopenia or thrombocytopenia with anemia. Thus, since thrombo-
cytopenia was the only feature found in all the patients, the disorder
could, in the first instance, be regarded as an isolated thrombocy-
topenia or with thrombocytopenia variably associated with anemia
and/or neutropenia. However, the trilineage aplasia observed in the
oldest sibling suggests that the hematological picture worsens with
age. As a matter of fact, the clinical presentation of these patients
appears indistinguishable from that of subjects with CAMT due to
MPL mutations.
The first homozygous loss-of-function variant of THPO (p.R38C)
was reported in a Micronesian family presenting with a recessive
form of aplastic anemia (Dasouki et al, 2013). Bone marrow aplasia
was recognized at the age of 16 and 28 years in the two investigated
patients, and family history revealed that two siblings had died for
aplastic anemia in their adolescence. The paper did not report
whether in these subjects, bone marrow aplasia was preceded by a
history of congenital thrombocytopenia. Therefore, we cannot
exclude that also the Micronesian patients had a clinical course
similar to that of CAMT, even if globally less severe, given that
marrow aplasia was diagnosed during their adolescence or later.
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Figure 3. The mutant THPO-conditioned culture supernatants are markedly deficient in sustaining proliferation of UT7-TPO cells.
Cell proliferation measured in n = 3 independent MTT assays and expressed as absorbance units of UT7-TPO cells incubated with medium containing 0.5 or 1.0 ll of THPO-
conditioned supernatants fromHEK293T cells transfected with wild-type (WT) or mutant (p.R119C and p.R38C) THPO-expressing or empty vectors. Recombinant human THPO
(rHuTHPO) at the concentration of 10 ng/ml was also used as control. Data are presented as means  SD. The asterisk (*) indicates a P-value < 0.01with respect toWT (two-
tailed Student’s t-test). The exact P-values are reported in Appendix Table S2.
Source data are available online for this figure.
Table 3. THPO concentrations measured in the conditioned
supernatants from HEK293T cells transfected with wild-type or
mutant THPO-expressing or empty vectors.
THPO (ng/ml)
(mean  SD)
Wild-type THPO 239.9  11.4
p.R119C THPO 10.6  2.4a
p.R38C THPO 10.7  3.9a
Empty vector 0
Supernatants were collected 24 and 48 h after transfection and then pooled
in a ratio of 1:1 (Dasouki et al, 2013).
aP < 0.05 with respect to wild-type THPO.
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Very recently, Seo and colleagues reported five individuals from
three consanguineous families carrying another two homozygous
mutations (p.R99W and p.R157*) of THPO (Seo et al, 2017). Like
our patients, these subjects presented with hypo-megakaryocytic
thrombocytopenia without or with anemia or neutropenia, which
progressed to trilineage bone marrow aplasia in early childhood.
Thus, these patients also had a clinical picture indistinguishable
from that of CAMT caused by MPL receptor defects.
Considering that missense mutations can be regarded as variants
of uncertain significance, we carried out in vitro studies to deter-
mine the effect of the p.R119C substitution on the THPO function.
When probed at the same concentration of the wild-type protein,
the p.R119C THPO was defective in sustaining the growth of a
THPO-dependent cell line and in stimulating the MPL receptor.
Moreover, we found that p.R119C strongly affects secretion of
THPO. In fact, in cell extracts, the mutant THPO was stable and
expressed at comparable levels than those of wild-type protein, but
its concentration in the culture supernatants was markedly lower
than that of the wild-type form. Therefore, although the amino acid
substitution does not affect stability of THPO, it is likely to impair
the cellular trafficking, preventing the cytokine from being secreted.
Of note, the THPO serum concentration measured in our patients
was consistent with this mechanism. In fact, since the endogenous
THPO is cleared from circulation by megakaryocytes and platelets,
the serum or plasma THPO levels are markedly increased in all
forms of bone marrow aplasia or hypoplasia, including CAMT due
to MPL mutations (Dame, 2001; Ballmaier & Germeshausen, 2009;
Olnes et al, 2012; Ballmaier et al, 2015). At variance, the serum
THPO concentration was not increased in our patients and thus
inappropriately lower than expected on the basis of their megakary-
ocyte–platelet mass. Like p.R119C, also p.R38C led to defective
secretion of THPO, a finding that was consistent with the “normal”
or low serum levels of THPO found in the other individuals carrying
loss-of-function mutations of THPO (Dasouki et al, 2013; Seo et al,
2017). These observations suggest that measurement of the serum
THPO level could be useful to discriminate CAMT patients with
THPO mutations from those with MPL variants or other bone
marrow failure syndromes.
Moreover, R119 resides in the domain that binds the MPL
receptor and is highly conserved among orthologs, as well as in
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Figure 4. The p.R119C and p.R38C THPO proteins are stable as the wild-type THPO.
A Representative images of immunoblotting of HEK293T cells transfected with wild-type or mutant (p.R119C and p.R38C) THPO-expressing vectors. Cell lysates were
prepared just before treatment with cycloheximide (CHX) (time 0) and 8, 24, and 48 h after the addition of CHX in order to block de novo protein synthesis (CHX
chase assay). DMSO alone was used as control in the WT sample. GAPDH was used as loading control.
B Densitometric analysis of the bands obtained in n = 3 independent experiments. THPO amount was measured as THPO/GAPDH ratio and expressed as the percentage
of the amount measured at time 0 in each condition (Relative protein, %). Of note, the expression of wild-type THPO after CHX treatment was significantly lower
compared with DMSO alone at each time point (P < 0.05, two-tailed Student’s t-test), confirming that protein synthesis was efficiently blocked by CHX treatment.
Data are presented as mean  SD. The exact P-values are reported in Appendix Table S3.
Source data are available online for this figure.
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the human homolog EPO. Like EPO, THPO binds to the extracel-
lular domain of MPL through two sites of different (low and
high) affinity (Syed et al, 1998; Feese et al, 2004). Since residue
119 is involved in polar interactions of the low affinity site (Feese
et al, 2004), substitution of arginine with cysteine is predicted to
reduce but not abolish the binding of THPO to MPL. Consistent
with this hypothesis, the functional studies demonstrated that the
p.R119C THPO retains approximately 50% of the activity of the
wild-type form, when measured as proliferation of THPO-depen-
dent cells or activation of signaling kinases downstream of the
MPL receptor.
THPO-mimetic drugs represent an appealing therapeutic option
for the cytopenias caused by THPO mutations (Basciano & Bussel,
2012). Consistently, romiplostim was effective in increasing
platelet count in all our patients, as well as in increasing hemo-
globin concentration and neutrophil count in subjects presenting
with anemia and/or neutropenia. Beside the hematological
response, romiplostim induced remission of spontaneous bleeding
and transfusion independence in the proband and his brother, as
well as stable remission of recurrent infections in the proband.
These clinical responses were maintained after a follow-up of
more than 6 years in both subjects. Further observations are
required to ascertain if romiplostim is able to definitively prevent
recurrence of aplastic anemia in the propositus and avoid its
occurrence in his two siblings. However, the prolonged trilineage
response to the drug observed in the proband, despite the use of a
very low dose and of a non-conventional administration schedule
due to logistic reasons, allows us to hope that the drug will be
effective also in this regard. Consistent with our observations,
trilineage response to romiplostim was achieved by two affected
individuals homozygous for the p.R99W or p.R157* mutations of
THPO (Seo et al, 2017).
Distinguishing CAMT associated with THPO mutations from that
caused by alterations of MPL mutations, as well as from the other
forms of juvenile bone marrow failure syndrome, has relevant
consequences in the clinical practice. Although HSCT is the corner-
stone of treatment for these forms, transplantation is not expected
to be effective in subjects with cytopenias deriving from defects in
THPO. In fact, four patients with the p.R99W or p.R157* mutations
underwent HSCT, which resulted in engraftment failure or persistent
aplasia despite donor cell engraftment even after repeated transplan-
tations (Seo et al, 2017). Three children died early after HSCT. After
lack of response to HSCT despite full donor chimerism, the fourth
patient was started on romiplostim obtaining a dramatic improve-
ment of pancytopenia. Altogether, our and previous observations
highlight the importance of distinguishing patients with THPO muta-
tions from those with MPL defects or other juvenile bone marrow
failure syndromes.
Of interest, a homozygous (p.R150Q; p.R177Q in the precursor
protein) mutation in the EPO gene was recently identified in two
siblings presenting with congenital hypoplastic anemia (Kim et al,
2017). The amino acid substitution did not affect the release of
EPO, whose levels were markedly increased in patients’ plasma, or
the cytokine affinity for its receptor, which was only mildly
reduced. Instead, it altered the ligand–receptor binding kinetics,
causing impaired receptor dimerization dynamics even at maxi-
mally potent concentrations of the p.R150Q EPO. This, in turn,
resulted in a significantly altered pattern of activation of the JAK2-
dependent signaling effectors downstream of the EPO receptor
(Kim et al, 2017). Thus, different mutations in the two highly
homologous cytokines THPO and EPO can cause defects in the
signaling pathways downstream of their receptors through very
different mechanisms. Like in patients with THPO mutations, the
alteration of EPO caused a disorder unresponsive to HSCT, but
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Figure 5. The p.R119C and p.R38C variants result in reduced functional activity of THPO protein.
Cell proliferationmeasured in n = 3 independent MTT assays and expressed as absorbance units of UT7-TPO cells incubated withmedium containing different concentrations
(60, 120, or 240 pg/ml) of THPO obtained from HEK293T cells supernatants transfected with wild-type (WT) or mutant (p.R119C and p.R38C) THPO-expressing or empty
vectors. Data are presented as means  SD. The asterisk (*) indicates a P-value < 0.05, while (**) indicates a P-value < 0.01 with respect to WT (two-tailed Student’s t-test).
The exact P-values are reported in Appendix Table S4.
Source data are available online for this figure.
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Figure 6. Defective activation of signaling kinases downstream of the MPL receptor.
A Representative images of immunoblotting of UT7-TPO cells recapitulating conditions of the cell proliferation assays shown in Fig 3 (incubation with 0.5 ll of HEK293T
wild-type or mutant supernatants) and Fig 5 (incubation with 240 pg/ml of THPO from HEK293T wild-type or mutant supernatants). The supernatant (0.5 ll)
obtained after transfection of the empty vector (EV) was used as a negative control. Commercial recombinant human THPO (rHuTHPO) at 10 ng/ml was used as the
positive control condition. The analysis investigated the phosphorylated forms of STAT5, ERK, and AKT (p-STAT5, p-ERK, and p-AKT) and the total form of the three
kinases (STAT5, ERK, and AKT). GAPDH was used as loading control.
B Densitometric analysis of the bands obtained in n = 3 independent experiments. Protein phosphorylation was expressed as the ratio between the phosphorylated and
the total forms of each protein. Data are presented as means  SD. The asterisk (*) indicates a P-value < 0.05, while (**) indicates a P-value < 0.01 with respect to
WT (two-tailed Student’s t-test). The exact P-values are reported in Appendix Table S5.
Source data are available online for this figure.
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treatable using a substitutive therapy that replaces the activity of
the defective cytokine. In fact, the proband carrying the homozy-
gous p.R150Q EPO mutation underwent HSCT; unfortunately, he
showed persistence of severe anemia despite the achievement of
full donor chimerism, and died for complications stemming from
the transplantation procedure. Instead, his younger sister, who
shared the same genotype and clinical picture, was treated with
recombinant human EPO obtaining complete remission of anemia
(Kim et al, 2017).
In conclusion, mutations of the THPO gene cause a form of
CAMT that can be treated with THPO-receptor agonists. The disor-
der should be suspected in children or young adults presenting with
hypo-megakaryocytic thrombocytopenia with or without other
peripheral cytopenias, including those with an apparently acquired
aplastic anemia. Measurement of the serum THPO level could repre-
sent a valuable tool to identify patients with defective THPO. Recog-
nizing these patients is essential for their correct management
avoiding the use of invasive and unnecessary treatments, such as
HSCT and immunosuppressive drugs.
Materials and Methods
Patients
Clinical investigations of the proband and his relatives were carried
out from July 2009 to January 2017 at the Ain Shams University
Children’s Hospital, Cairo, Egypt. Romiplostim was administered at
the same institution. The patients’ parents signed written informed
consent for the studies, for treatment with romiplostim, and for
reporting their clinical data in an anonymous form. All the proce-
dures were performed in accordance with the principles of the
Declaration of Helsinki.
Mutational screening
The MPL (NM_005373.2) and THPO (NM_000460) coding exons
and the respective exon–intron boundaries were amplified by PCR.
Amplification reactions were carried out in a final volume of 35 ll
containing 100 ng of DNA, 17.5 ll of KAPA2G Fast Hot Start Ready
Mix (Kapa Biosystems, Resnova, Cape Town, South Africa), and
1.75 ll of a 10 pmol solution of each primer (primers sequences
available upon request). PCR products were sequenced using an
ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit
and an ABI 310 Genetic Analyzer (Applied Biosystems, Foster City,
CA, USA). Nucleotide A of the ATG translation initiation start site of
the THPO gene cDNA in GenBank sequence NM_000460.3 is indi-
cated as nucleotide +1.
Bioinformatic analyses
The effect of the missense variations was evaluated using five
pathogenicity prediction programs: PoliPhen-2 (http://genetics.
bwh.harvard.edu/pph2/), Mutation Taster (http://www.mutationta
ster.org/), Mutation Assessor (http://mutationassessor.org/r3/),
SIFT (http://sift.jcvi.org) and, CADD (http://cadd.gs.washington.ed
u). Protein structures were analyzed with the graphic program Pymol
v1.3 (The PyMOL Molecular Graphics System, Schro¨dinger, LLC).
Generation of THPO constructs
A pcDNA3.1+-C-DYK expression vector containing cDNA of human
THPO (OHU10732, GenScript, Hong Kong, China) was used for
mutagenesis. The c.112C>T (p.R38C) and c.335C>T (p.R119C)
mutations were generated using specific primers R38C_F (50-GTAA
ACTGCTTTGTGACTCCCATGTCC-30) and R38C_R (50-GGACATGGG
AGTCACAAAGCAGTTTAC-30) or R119C_F (50-CTGGACAGGTCT
GTCTCCTCCTTGGGG-30) and R119C_R (50-CCCCAAGGAGGAGAC
AGACCTGTCCAG-30) and the QuikChange Multi Site-Directed Muta-
genesis Kit (Stratagene, Agilent, San Diego, CA, USA). To confirm
the wild-type and the mutant sequences, constructs were sequenced
as above.
Production of THPO-conditioned supernatants
Human embryonic kidney (HEK) 293T cells (National Institute for
Cancer Research, Genoa, Italy) were maintained in Dulbecco’s
modified Eagle’s medium with 20% fetal bovine serum (FBS)
(Lonza Group Ltd, Basel, Switzerland). Aliquots of 7 × 105 cells
were seeded in six-well culture plates and transfected 24 h later
with the constructs harboring cDNA for wild-type THPO, p.R119C
THPO, p.R38C THPO, or the empty vector, using the Lipofectamine
2000 reagent (Life Technologies, Carlsbad, CA, USA) according to
the manufacturer’s instructions (reagent/DNA ratio of 2.5:1). THPO-
conditioned supernatants were collected 24 and 48 h after transfec-
tion, filtered, and frozen at 80°C until use. For immunoblotting,
MTT or ELISA assays, media collected 24 and 48 h after transfection
were pooled in a 1:1 ratio (Dasouki et al, 2013).
MTT cell proliferation assay
UT7-TPO human megakaryoblastic cell line is a kind gift from Dr.
Hana Raslova (Institute Gustave Roussy, Villejuif, France). UT7-
TPO cells were maintained in MEM alpha medium with 10% FBS
and 5 ng/ml GM-CSF (PeproTech, London, UK). After starvation for
any cytokines for 16 h, aliquots of 1 × 104 cells were seeded in 96-
well culture plates and incubated with 250 ll of MEM Alpha culture
medium containing 0.5 or 1.0 ll of wild-type or mutant THPO-
conditioned supernatants (Dasouki et al, 2013). The same assay
was also carried out using the MEM alpha medium containing the
THPO-conditioned supernatants volumes required to reach the final
THPO concentrations of 60, 120, or 240 pg/ml (total volume 250 ll
per well). As a negative control, the empty vector medium was used
at the same volume of the medium used at the highest volume in
the same experiment. Commercial recombinant human THPO
(PeproTech) at 10 ng/ml, a concentration that induces maximal
UT7-TPO stimulation in our experimental setting, was used in
parallel as the positive control condition. After 3 days of culture,
aliquots of 100 ll were transferred to a microplate and treated with
10 ll of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) (Roche, Basel, Switzerland). After incubation for
6 h, 100 ll of dimethylsulfoxide was added to solubilize the MTT
formazan crystals. After further overnight incubation, samples were
shacked for 10 min in a titer shaker, and absorbance was measured
at 562 nm by an Eppendorf BioPhotometer (Hamburg, Germany).
Absorbance value of the culture medium alone was subtracted from
the samples’ values. Each experiment was performed in duplicate
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and data presented represent the mean  SD of three separate
experiments.
Analysis of signaling kinases downstream MPL
After starvation for any cytokines for 16 h, aliquots of 2.5 × 105
UT7-TPO cells were stimulated for 30 min at 37°C with wild-type,
p.R119C, or p.R38C THPO-conditioned media and phosphorylation
of ERK1/2, STAT5, and AKT was investigated by immunoblotting.
To recapitulate the conditions of the proliferation assay, cells were
incubated with an equal volume of wild-type or mutant supernatants
(0.5 ll), or with the same concentration of wild-type or mutant
THPO (240 pg/ml). The supernatant obtained after transfection of
the empty vector was used at a volume of 0.5 ll as negative control.
In all the cases, THPO-conditioned supernatants were diluted in
MEM alpha culture buffer to reach a total volume of 250 ll per well
(Dasouki et al, 2013). Commercial recombinant human THPO
10 ng/ml was used as the positive control condition. After washing
with PBS, cells were lysed in IP buffer (10 mM Tris, 158 mM NaCl,
1% Triton X-100, 1% Na-deoxycholate, 0.1% sodium dodecyl sulfate
(SDS), 5 mM EGTA, pH 7.2) with 2% protease and phosphatase inhi-
bitor cocktail (Sigma, St. Louis, MO, USA). General procedures of
immunoblotting have been previously described in details (Necchi
et al, 2013). Membranes were probed with the following antibodies:
rabbit monoclonal C11C5 anti-phospho-STAT5, diluted 1:1,000 (Cell
Signaling Technology, MA, USA); rabbit monoclonal 3H7 anti-total
STAT5, 1:1,000 (Cell Signaling); rabbit polyclonal anti-phospho-
AKT, 1:1,000 (Cell Signaling); rabbit polyclonal anti-total AKT,
1:2,000 (Cell Signaling), rabbit polyclonal anti-phospho-ERK1/2,
1:1,000 (Cell Signaling); mouse monoclonal 137F5 anti-ERK1/2,
1:2,000 (Cell Signaling); rabbit monoclonal EPR16891 anti-GAPDH,
1:5,000 (Abcam). The appropriate HRP-conjugated secondary anti-
bodies (Dako, Glostrup, Denmark) were used for detection. Densito-
metric analysis was performed by ImageJ software. Protein
phosphorylation was expressed as the ratio between the phosphory-
lated form and the total form of each protein. Data are represented as
the mean  SD of three separate experiments.
Immunoblotting detection of transfected THPO
Lysates prepared 24 and 48 h after transfection of HEK293T cells
were pooled in a 1:1 ratio for immunoblotting (Dasouki et al, 2013),
or analyzed separately. Membranes were probed with the following
monoclonal antibodies: rabbit EPR14948 against human THPO,
diluted 1:2,000 (Abcam, Cambridge, UK); mouse M2 against FLAG
tag epitope, 1:1,000 (Sigma); mouse AC-15 against b-actin, 1:5,000
(Sigma). The appropriate HRP-conjugated secondary antibodies
(Dako, Glostrup, Denmark) were used for detection. Densitometric
analysis was performed by ImageJ software. Immunoblotting was
performed on HEK293T cells obtained by the same three separate
transfection experiments performed for the collection of THPO-
conditioned supernatants for ELISA and MTT assays. Data represent
the mean  SD of all experiments.
Cycloheximide chase assay
Cycloheximide chase assay for investigation of stability of THPO
proteins was performed as previously reported (Zhang et al, 2016;
Marconi et al, 2017). Briefly, cycloheximide 100 lg/ml diluted in
DMSO was added to HEK293T cells 24 h after transfection with
wild-type, p.R119C, or p.R38C THPO, in order to block de novo
protein synthesis. Control conditions were carried out by adding the
same amount of DMSO alone to the HEK293T transfected with wild-
type THPO. Cells were collected and lysed just before the addition
of cycloheximide or DMSO (time 0) and 8, 24, and 48 h after the
addition of cycloheximide or DMSO. Proteins were analyzed at each
time point by immunoblotting as reported above. GAPDH was used
as loading control. THPO amount was measured as THPO/GAPDH
ratio and expressed as the percentage of the amount measured at
time 0 in each condition. Data represent the mean  SD of three
separate experiments.
ELISA measurement of THPO concentration
THPO concentration in patients’ plasma or in the THPO-conditioned
supernatants was assessed by the Quantikine ELISA–Human Throm-
bopoietin Immunoassay Kit (R&D system, Minneapolis, MN, USA)
according to the manufacturer’s instructions. Each sample was
assayed in duplicate. Optical density was read at 450 nm with wave-
length correction at 540 nm on a microplate reader model 680 (Bio-
Rad). ELISA assay was performed on the conditioned media of
The paper explained
Problem
Congenital amegakaryocytic thrombocytopenia is an inherited disease
characterized by severe low platelet count since birth, which is due to
absence of megakaryocytes (progenitor cells of platelets), and progres-
sion to aplastic anemia during childhood. CAMT is always fatal unless
children are treated with HSCT, the only treatment available so far.
Mutations of MPL, the gene encoding for the receptor of thrombopoi-
etin, have previously been associated with CAMT but not in all
affected individuals, suggesting that other genes have yet to be
identified.
Results
In a family with three children affected with CAMT, we excluded the
presence of mutations in the MPL gene. Instead, we found that a
novel mutation in the THPO gene, which encodes for thrombopoietin,
was the cause of the disease. The mutation induces low thrombopoi-
etin production and defective binding of thrombopoietin to its recep-
tor MPL, suggesting that both quantitative and qualitative defects of
thrombopoietin are responsible for the disease. The three children
were treated with romiplostim, a drug that mimics the effects of
thrombopoietin, and thus is expected to compensate the above
defects. All of them obtained a significant improvement of blood cell
counts, remission of bleeding and infections, and independence
from transfusions, which was maintained after an up to 6.5-year
observation.
Impact
Patients with CAMT caused by THPO mutation can be effectively
treated with romiplostim. Considering that thrombopoietin is mainly
produced by the liver and other cells extrinsic to hematopoietic cells,
these patients are not expected to benefit from hematopoietic stem
cell transplantation. Therefore, distinguishing patients with THPO
mutations from those with MPL mutations is of fundamental impor-
tance not only to give the appropriate treatment, but also to avoid
the use of unnecessary and risky procedures.
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HEK293T derived from three different transfection experiments.
Data represent the mean  SD of all experiments.
Expanded View for this article is available online.
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